Life Science and Medical News from Around the Globe
CytoDyn CEO on DrBeen Webcast July 4, 2020 (9 pm EDT) (YouTube & FB) to Discuss with Mobeen Syed, MD, the Many Potential Opportunities for Anti-CCR5 Monoclonal Antibody Leronlimab, Including Treatment of COVID-19, HIV, & Triple-Negative Breast Cancer
CytoDyn Inc. (OTC.QB: CYDY), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, has announced that Nader Pourhassan, PhD, President and Chief Executive Officer of CytoDyn will be interviewed on the DrBeen webcast hosted by Mobeen Syed, MD, on Saturday, July 4, 2020 at 9:00 pm EDT (6 pm PDT, 7 pm MDT, and 8 pm CDT). The interview will be available simultaneously on two channels:
YouTube - DrBeen Medical Lectures
Link: https://www.youtube.com/c/USMLEOnline
Facebook: DrBeen Medical
Link: https://m.facebook.com/drbeenmedical
CYTODYN & CORONAVIRUS DISEASE 2019(COVID-19): CytoDyn has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and enrollment continues in CytoDyn’s Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country. SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.